Trials / Completed
CompletedNCT05932277
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
A Phase 1 Open-label Study to Assess the Effect of BMS-986419 on the Single Dose Pharmacokinetics of Probe Substrates (Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, and Fexofenadine) in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the effect of BMS-986419 on the pharmacokinetics (PK) of single doses of caffeine (CYP1A2 substrate), bupropion (CYP2B6 substrate), midazolam (CYP3A4 substrate), flurbiprofen (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and fexofenadine (P-gp substrate), in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986419 | Specified dose on specified days |
| DRUG | Caffeine | Specified dose on specified days |
| DRUG | Bupropion | Specified dose on specified days |
| DRUG | Flurbiprofen | Specified dose on specified days |
| DRUG | Omeprazole | Specified dose on specified days |
| DRUG | Midazolam | Specified dose on specified days |
| DRUG | Fexofenadine | Specified dose on specified days |
Timeline
- Start date
- 2023-06-29
- Primary completion
- 2023-09-13
- Completion
- 2023-09-13
- First posted
- 2023-07-06
- Last updated
- 2023-10-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05932277. Inclusion in this directory is not an endorsement.